The answer so far

Burning fat means using fat as fuel; fat loss means a reduction in stored body fat over time; weight loss means the number on the scale decreases. They can occur together, but none is a synonym for the others. “Fat-busting” is a marketing phrase, so ask what a study actually measured.12

On this page
  1. What does burning fat actually mean?
  2. How is fat loss different from weight loss?
  3. Is all abdominal fat the same?
  4. What does “fat-busting” prove?
  5. Where do medicines and peptides fit?
  6. Sources
Follow this question
Fat burning, fat loss and weight loss: what is the difference? Choose a step to explore this subject in more detail.
  1. 1What does burning fat actually mean?
  2. 2How is fat loss different from weight loss?
  3. 3Is all abdominal fat the same?
  4. 4What does “fat-busting” prove?

What does burning fat actually mean?

The body uses a mixture of fuels, including fat and carbohydrate, and that mixture changes with circumstances. A product may claim to increase a short-term measure of fat use or metabolism. That does not by itself show how much stored body fat changes over weeks or months, or whether a person’s health improves. NIH notes that some supplement ingredients have short-term metabolic findings while evidence for weight loss is inconclusive.

To see how the distinction was measured in a trial, read the tirzepatide fat and lean-mass study or the tesamorelin visceral-fat study.

For a clear introduction to where these tissues are and how they are measured, see visceral fat versus fat under the skin.1

How is fat loss different from weight loss?

Body weight includes fat, water, muscle, bone and other tissues. A lower scale reading does not say which component changed, and weight can fluctuate for reasons besides changes in stored fat. Body-composition methods can estimate fat and fat-free mass, but they have limitations. Fat-free or lean mass is not identical to muscle alone. The question is what was measured and how reliably.2

Is all abdominal fat the same?

Fat under the skin is called subcutaneous fat. Visceral fat is stored deeper around internal organs. A waist measurement, a body-composition estimate and an imaging scan answer different questions. For example, a tesamorelin trial in a specific group measured visceral fat by scan; it was not simply a trial of a general “belly-fat burner”. See what the tesamorelin trial measured.32

What does “fat-busting” prove?

Nothing on its own: it is not a standard clinical outcome. Ask whether the claim refers to a cell experiment, a brief change in fuel use, body-fat measurements or a controlled study of weight over time. An ingredient in a laboratory, an anecdote and a complete product in a human trial are different evidence. A claim about a supplement does not prove the effect of a peptide medicine, or vice versa. Local “fat-dissolving” injections describe a separate approach; see how they differ from fat burning and weight loss.1

Where do medicines and peptides fit?

Some approved products act on appetite and fullness; other compounds are marketed around metabolism or body composition. Their proposed mechanisms, evidence and legal status differ. Follow the guide to weight-loss peptides and appetite, or start with the broader weight and appetite hub.45

Sources, kept close.

Selected supporting sources; this is not a complete literature review.

  1. Dietary Supplements for Weight Loss: Health Professional Fact SheetNIH Office of Dietary Supplements · Authoritative evidence overview; supplements, not peptide medicinesAccessed 2026-11-05
  2. Overweight and obesity in adultsNational Institutes of Health · Public health overviewAccessed 2026-11-05
  3. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIVNew England Journal of Medicine · Randomised placebo-controlled trial; United States and Canada; 2007; manufacturer fundedAccessed 2026-11-04
  4. FDA Approves New Medication for Chronic Weight ManagementU.S. Food and Drug Administration · US regulator approval announcementAccessed 2026-11-05
  5. Pharmacy Compounding Advisory Committee presentation: AOD-9604U.S. Food and Drug Administration · Regulator advisory presentation summarising sponsor-reported trial; United States; December 2024Access checked 2026-11-04 · OPTIONS study results are regulator-reported sponsor information; complete independent study report not reviewed. The AOD-9604 presentation appears later in the combined meeting deck; OPTIONS is on PDF pages 103–104.